世界の高血圧治療薬市場動向：2005〜2010年

Abstract

The world hypertension market generated over $25 billion in 2004, with steady growth from the previous year. In this report, visiongain forecasts that revenues in the world hypertension market will grow to nearly $30 billion per year by 2010.

This market report examines the prospects of the world hypertension market from 2005-2010. This market is one of the largest and most important in the pharmaceutical industry. Furthermore, the treatment of hypertension is a central part of cardiovascular healthcare itself at the forefront of public health.

This report examines the hypertension market critically through a comprehensive review of available information, including that from commercial databases, pipeline reports, academic research and consultation with international experts. Visiongain provides forecasting, SWOT analysis and the assessment of unmet needs to provide comprehensive financial forecasts, in-depth analyses and informed opinion.

In particular, this report concentrates on the following important issues:

• The current state of the world market for drugs to treat hypertension
• Drivers and opportunities in the hypertension market
• Restraints and threats in the hypertension market
• How the overall hypertension market is likely to grow between 2005-2010
• Prospects for the current market leading drugs between 2005-2010
• The potential for generics manufacturers to penetrate this market further
• A breakdown of the world hypertension market into the principal geographical markets, with estimates of potential treatment populations and forecasted revenues in 2010
• A discussion of unmet needs in the world hypertension market, with contributed opinions from experts
• Detailed information on pipeline products and line extensions in this market

Why You Should Buy This Report

• To receive a comprehensive analysis of the prospects of the world hypertension market from 2004-2010
• To find out predicted revenues, growth rates and market shares for all the leading antihypertensive drugs from 2005-2010
• To determine the forces that influence the hypertension market, especially:
  • Competitive characteristics
  • Drivers and restraints
  • Strengths, weaknesses, opportunities and threats
  • Unmet needs according to world experts, with gaps in the market exposed
• To find out the prospects for antihypertensive drugs in the leading geographical markets:
  • Potential treatment populations
  • Potential 2010 revenues in the leading 7 markets
  • Potential for growth of the hypertension market in other regions
• To find out about pipeline developments for treating hypertension, as well as recent product launches

Table of Contents

1. Executive Summary - Hypertension is a Dangerous Medical Condition and is a Serious Cause of Mortality Worldwide

2. Introduction to Hypertension

• 2.1 An Overview of Hypertension
• 2.2 Symptoms of Hypertension and Diagnosis of the Condition
• 2.3 Causes of Hypertension
• 2.4 Primary Hypertension
• 2.5 Secondary Hypertension
• 2.6 Pulmonary Hypertension
• 2.7 Epidemiology of Hypertension
• 2.8 Links with Other Disorders
• 2.9 The Treatment of Hypertension
  • 2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
  • 2.9.2 Treatment Targets and the Selection of Drugs
  • 2.9.3 Beta Blockers
  • 2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 2.9.5 Calcium-Channel Blockers
  • 2.9.6 Angiotensin II Blockers
  • 2.9.7 Alpha Blockers
  • 2.9.8 Diuretics
  • 2.9.9 Other Drugs
  • 2.9.10 Treatment of Pulmonary Hypertension
• 2.10 The Prospects for Patients

3. The World Hypertension Market, 2004-2010

• 3.1 Growing Demand and Shifting Internal Dynamics in the World Antihypertensive Market, 2004-2010
• 3.2 Novartis to Become the Leading Company in the 2010 Hypertension Market
• 3.3 Angiotensin II Blockers to Continue Their Domination of the Antihypertensive Market, 2005-2010
• 3.4 Other Classes of Antihypertensive Drug Display High Revenues during 2004-2010
• 3.5 Calcium Channel Blockers - Declining Revenues due to Competition
• 3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
• 3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market
• 3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
• 3.9 Increasing Potential for Blockbuster Revenues During 2004-2010
• 3.10 Competition in the Antihypertensive Market to Become Increasingly Intense
• 3.11 Monotherapy or Combination Therapy?
• 3.12 Diuretic Agents Retain Importance

4. The World Market for Angiotensin II Blockers, 2004-2010

• 4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
  • 4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
  • 4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
• 4.2 Diovan to Take Market Leadership from Norvasc by 2010
  • 4.2.1 Diovan Benefits from Further Clinical Studies
• 4.3 Cozaar/Hyzaar - High Revenues with Continued Growth
  • 4.3.1 Further Developments for Cozaar/Hyzaar
• 4.4 Blopress - Another Strong Performer
  • 4.4.1 Additional FDA Approval for Blopress
• 4.5 Sanofi-Aventis' Aprovel/Avapro to Maintain Steady Growth
  • 4.5.1 Avaprovel/Avapro Benefits from Continuing Development
• 4.6 Bristol-Myers Squibb's Avapro/Avalide Will Also Benefit from This Growing Market
• 4.7 Atacand - Reversion of Licensing Rights to Original Manufacturer
• 4.8 Boehringer Ingelheim's Micardis Will Achieve Blockbuster Revenues By 2010
  • 4.8.1 Micardis Shows Potential Metabolic Benefits
  • 4.8.2 Micardis Benefits from Further Clinical Studies
• 4.9 Astellas Pharmaceutical's Micardis Will Achieve Very High Growth Over The Forecast Period
  • 4.9.1 Further Clinical Studies May Confer a Market Advantage to Astellas' Micardis
• 4.10 Provas/Miten - Only Modest Success is Predicted for This Drug
• 4.11 Benicar's Revenue Growth Set to Continue Steadily
  • 4.11.1 Further Licensing Agreements for Benicar
  • 4.11.2 Promising Results from Further Clinical Study
• 4.12 The Angiotensin II Blockers: Summary and Conclusions

5. The World Market for Calcium Channel Blockers, 2004-2010

• 5.1 Increased Competition Will Lower Revenues
• 5.2 Norvasc - 2004 Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
  • 5.2.1 Norvasc Benefits from Further Clinical Testing
  • 5.2.2 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
• 5.3 Adelat - The Second Largest Calcium Blocker, But Significantly Behind Norvasc
• 5.4 Plendil - Declining Revenues Predicted
• 5.5 Coniel Will Sustain Revenues
• 5.6 Herbesser Faces Slight Decline in Revenues
  • 5.6.1 The Outcome of Further Clinical Studies on Herbesser
• 5.7 Lercanidipine - Optimism Due to Further Launches and Product Development
  • 5.7.1 Lercandipine to Be Released in More Countries
  • 5.7.2 Lercandipine Receives Continuing Product Development
• 5.8 Perpidine/Perpidine LA - Revenue Decline Predicted
• 5.9 Calslot Will Show Moderate Revenue Growth
• 5.10 Lower Revenue Calcium Blockers: Nivadil, Verelan PM and Cardizem LA
  • 5.10.1 Cardizem LA Is Undergoing Further Development
• 5.11 The Calcium Blockers: Summary and Conclusions

6. The World Market for Angiotensin Converting Enzyme (ACE) Inhibitors, 2004-2010

• 6.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
  • 6.1.1 ACE Inhibitors Will Retain Prominence in The Market
• 6.2 Delix/Tritace Will Lose Predominance In This Class
  • 6.2.1 Licensing Agreements for International Distribution
  • 6.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
• 6.3 Lotrel Will Become The ACE Inhibitor With The Highest Revenues
• 6.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
  • 6.4.1 Additional Clinical Studies and Product Development to Benefit Vasotec
• 6.5 Accupril/Accuretic - Revenues Set To Fall
  • 6.5.1 Accupril/Accuretic Faces Patent Challenges
• 6.6 Zestril - Expiry of Patent Leads to Continuing Decline
• 6.7 Monopril Faces a Steep Decline In Revenue
• 6.8 Tanatril Is Likely to Struggle to Maintain Revenues
• 6.9 ACE Inhibitors With Lower Revenues: Acecol and Longes
• 6.10 The ACE inhibitors: Summary and Conclusions

7. The World Market for Beta-Blockers, 2004-2010

• 7.1 Beta Blockers Will Retain Their Niche in a Highly Competitive Market
  • 7.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
• 7.2 Toprol-XL/Seloken Will Become the Second Most Important Beta Blocker
  • 7.2.1 Toprol-XL Faces Patent Challenges
• 7.3 Coreg Is Set to Lead the Beta Blocker Class
  • 7.3.1 Coreg May Benefit From Further Clinical Studies
• 7.4 Maintate Faces Declining Revenues
• 7.5 The Beta Blockers: Summary and Conclusions

8. The World Market for Alpha Blockers, 2004-2010

• 8.1 Alpha blockers Will Defend Their Position in the Hypertension Market
  • 8.1.1 Alpha Blockers Are Also Used to Treat BPH
  • 8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
• 8.2 Cardura Will Dominate the Alpha Blocker Class
• 8.3 Catapresan Will Be Second Largest Drug In Its Class
• 8.4 Ebrantil Will Have Lowest Market Share in Class
• 8.5 The Alpha Blockers: Summary and Conclusions

9. An Analysis of Factors That Influence the Hypertension Market

• 9.1 SWOT Analysis of the Hypertension Market
• 9.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
• 9.3 The Hypertension Market Has Opportunities for Continuing Growth
• 9.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
• 9.5 Advances in Technology Are Likely to Bring Benefits to the Market
• 9.6 The Principal Restraints in the Hypertension Market
• 9.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
• 9.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
  • 9.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
  • 9.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
• 9.9 Comparative Studies - A Two Edged Sword

10. A Geographical Breakdown of the World Hypertension Market

• 10.1 The US Will Lead a High Revenue Global Market in 2010
• 10.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
• 10.3 Conclusions: There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale

11. Pipeline Drugs for Hypertension

• 11.1 Agents in Phase II of Clinical Development
  • 11.1.1 Darusentan From Myogen
  • 11.1.2 MC-4232 From Medicure
  • 11.1.3 MC-1 From Medicure
  • 11.1.4 MC-4262 From Medicure
  • 11.1.5 Ventavis From CoTherix For More Specialised Indication
• 11.2 Agents in Phase III of Clinical Development
  • 11.2.1 Aliskiren (SPP100) From Novartis
  • 11.2.2 Ambrisentan From Myogen
  • 11.2.3 Thelin From Encysive
  • 11.2.4 PW2101 From Penwest
  • 11.2.5 (S)-amlodipine From Sepracor
• 11.3 Recently Approved Agents for Treating Hypertension
  • 11.3.1 Revatio From Pfizer
  • 11.3.2 Nebivolol From Mylan
  • 11.3.3 Ventavis From CoTherix
  • 11.3.4 Ventavis Monopril-HCT From Ranbaxy
  • 11.3.5 Hydrochlorothiazide From Ivax
  • 11.3.6 Other Recently Approved Agents for Hypertension
• 11.4 An Overall Assessment of Pipeline Developments for the Hypertension Market

12. Conclusions: Hypertension Constitutes a Large Drugs Market With Scope For Expansion Worldwide

• 12.1 Hypertension is a Serious, Growing Problem Worldwide
• 12.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
• 12.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
• 12.4 The Pipeline for Hypertension Drugs is Strong
• 12.5 Continuing Public and Private Sector Investment is Required

TABLES

• Table 2.1, Categories for Blood Pressure Levels in Adults
• Table 2.2, Leading Beta-Blockers to Treat Hypertension, 2004
• Table 2.3, Leading ACE Inhibitors to Treat Hypertension
• Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension
• Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension
• Table 2.6, Leading Alpha Blockers to Treat Hypertension, 2004
• Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2004
• Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2004-2010
• Table 3.3, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010
• Table 3.4, Blockbuster Drugs in the World Hypertension Market, 2010
• Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2004-2010
• Table 4.2, Patent Expiry for Angiotensin II Blockers, 2005
• Table 4.3, World Market Shares (%) for Angiotensin II Blockers, 2004 and 2010
• Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2004-2010
• Table 5.2, Patent Expiry for Calcium Channel Blockers to Treat Hypertension
• Table 5.3, World Market Shares (%) for Calcium Blockers, 2004 and 2010
• Table 6.1, World Revenues ($m) for ACE Inhibitors, 2004-2010
• Table 6.2, Patent Expiry for ACE Inhibitors to Treat Hypertension
• Table 6.3, World Market Shares (%) for ACE Inhibitors, 2004 and 2010
• Table 7.1, World Revenues ($m) for Beta-Blockers, 2004-2010
• Table 7.2, Patent Expiry for Beta-Blockers to Treat Hypertension
• Table 7.3, World Market Shares (%) for Beta Blockers, 2004 and 2010
• Table 8.1, World Revenues ($m) for Alpha Blockers, 2004-2010
• Table 8.2, Patent Expiry for Alpha Blockers to Treat Hypertension
• Table 8.3, World Market Shares (%) for Alpha Blockers, 2004 and 2010
• Table 9.1, Leading Antihypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005
• Table 10.1, Estimated Hypertensive Patient Populations by Country, 2004
• Table 10.2, Estimated Revenues ($m) For Hypertension Drugs by Country and (%) World Market Shares, 2004 and 2010
• Table 12.1, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010
• Table 12.2, Revenues ($m) For Hypertension Drugs by Country, 2010

FIGURES

• Figure 3.1, World Revenues ($m) for the Classes of Leading Drugs to Treat Hypertension, 2004-2010
• Figure 3.2, World Market Share (%) for Hypertension by Class, 2004
• Figure 3.3, World Market Share (%) for Hypertension by Class, 2010
• Figure 3.4, Market Share (%) for Leading Hypertension Drugs by Company, 2004
• Figure 3.5, Market Share (%) for Leading Hypertension Drugs by Company, 2010
• Figure 3.6, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2004-2010
• Figure 3.7, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2004-2010
• Figure 4.1, World Revenues ($m) for All Angiotensin II Blockers, 2004-2010
• Figure 4.10, World Micardis (Boehringer Ingelheim) Revenues ($m), 2004-2010
• Figure 4.11, World Micardis (Astellas Pharma) Revenues ($m), 2004-2010
• Figure 4.12, World Provas/Miten Revenues ($m), 2004-2010
• Figure 4.13, World Benicar Revenues ($m), 2004-2010
• Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by drug, 2004-2010
• Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2004
• Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2010
• Figure 4.5, World Diovan/Co-Diovan Revenues ($m), 2004-2010
• Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2004-2010
• Figure 4.7, World Blopress Revenues ($m), 2004-2010
• Figure 4.8, World Aprovel/Avapro Revenues ($m), 2004-2010
• Figure 4.9, World Avapro/Avalide Revenues ($m), 2004-2010
• Figure 5.1, World Revenue ($m) for Calcium Channel Blockers, 2004-2010
• Figure 5.10, World Lercandidipine Revenues ($m), 2004-2010
• Figure 5.11, World Perpidine/Perpidine LA Revenues ($m), 2004-2010
• Figure 5.12, World Calslot Revenues ($m), 2004-2010
• Figure 5.13, World Nivadil Revenues ($m), 2004-2010
• Figure 5.14, World Verelan PM Revenues ($m), 2004-2010
• Figure 5.15, Cardizem LA Revenues ($m), 2004-2010
• Figure 5.2, World Revenues ($m) for Calcium Channel Blockers, 2010
• Figure 5.3, World Market Share (%) for Calcium Channel Blockers, 2004
• Figure 5.4, World Market Share (%) for Calcium Channel Blockers, 2010
• Figure 5.5, World Norvasc Revenues ($m), 2004-2010
• Figure 5.6, World Adalat Revenues ($m), 2004-2010
• Figure 5.7, World Plendil Revenues ($m), 2004-2010
• Figure 5.8, World Coniel Revenues ($m), 2004-2010
• Figure 5.9, World Herbesser Revenues ($m), 2004-2010
• Figure 6.1, World Revenue ($m) for All ACE Inhibitors, 2004-2010
• Figure 6.10, World Monopril Revenues ($m), 2004-2010
• Figure 6.11, World Tanatril Revenues ($m), 2004-2010
• Figure 6.12, World Acecol Revenues ($m), 2004-2010
• Figure 6.13, World Longes Revenues ($m), 2004-2010
• Figure 6.2a, World Revenues ($m) for the ACE Inhibitors, 2004-2010
• Figure 6.2b, World Revenues ($m) for Monopril, Tanatril, Acecol & Longes, 2004-2010
• Figure 6.3, World Market Share (%) for ACE Inhibitors, 2004
• Figure 6.4, World Market Share (%) for ACE Inhibitors, 2010
• Figure 6.5, World Delix/Tritace Revenues ($m), 2004-2010
• Figure 6.6, World Lotrel Revenues ($m), 2004-2010
• Figure 6.7, World Vasotec/Vaseretic Revenues ($m), 2004-2010
• Figure 6.8, World Accupril/Accuretic Revenues ($m), 2004-2010
• Figure 6.9, World Zestril Revenues ($m), 2004-2010
• Figure 7.1, World Revenues ($m) for the Beta Blockers: Total for Class, 2004-2010
• Figure 7.2, World Revenues ($m) for the Beta Blockers, 2004-2010
• Figure 7.3, World Market Share (%) for Beta-Blockers, 2004
• Figure 7.4, World Market Share (%) for Beta-Blockers, 2010
• Figure 7.5, World Toprol-XL/Seloken Revenues ($m), 2004-2010
• Figure 7.6, World Coreg Revenues ($m), 2004-2010
• Figure 7.7, World Maintate Revenues ($m), 2004-2010
• Figure 8.1, World Revenues ($m) for the Alpha Blockers: Total for Market, 2004-2010
• Figure 8.2, World Revenues ($m) for the Alpha Blockers, 2004-2010
• Figure 8.3, World Market Share (%) for Alpha Blockers, 2004
• Figure 8.4, World Market Share (%) for Alpha Blockers, 2010
• Figure 8.5, World Cardura Revenues ($m), 2004-2010
• Figure 8.6, Catapresan Revenues ($m), 2004-2010
• Figure 8.7, Ebrantil Revenues ($m), 2004-2010
• Figure 9.1, A SWOT Chart for the Hypertension Market, 2005-2010
• Figure 10.1, Estimated Hypertensive Populations by Country
• Figure 10.2, Revenues ($m) for Hypertension Drugs by Country, 2010